Holen Sie sich die Stockscreener-App
5.06
1.75%
-0.09
Schlusskurs vom Vortag:
$5.15
Offen:
$5.16
24-Stunden-Volumen:
649.42K
Relative Volume:
1.00
Marktkapitalisierung:
$164.56M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.25M
KGV:
-4.2664
EPS:
-1.186
Netto-Cashflow:
$-22.80M
1W Leistung:
-8.83%
1M Leistung:
-18.52%
6M Leistung:
-47.18%
1J Leistung:
+15.00%
1-Tages-Spanne:
$4.9701
$5.29
1-Wochen-Bereich:
$4.9701
$5.7399
52-Wochen-Spanne:
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Firmenname
Sagimet Biosciences Inc
Sektor
Branche
Telefon
(650) 561-8600
Adresse
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
5.06 | 167.49M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-03 | Eingeleitet | Guggenheim | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Equal Weight |
| 2025-08-11 | Eingeleitet | Wedbush | Outperform |
| 2025-08-07 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-24 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-12-06 | Eingeleitet | Oppenheimer | Outperform |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Herabstufung | Goldman | Buy → Neutral |
| 2024-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-25 | Eingeleitet | Leerink Partners | Outperform |
| 2023-08-08 | Eingeleitet | Goldman | Buy |
| 2023-08-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-08-08 | Eingeleitet | Piper Sandler | Overweight |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Sagimet Biosciences Inc Aktie (SGMT) Neueste Nachrichten
Top Sagimet Executives Quietly Unload Shares in Coordinated Insider Move - TipRanks
David Happel Sells 12,101 Shares of Sagimet Biosciences (NASDAQ:SGMT) Stock - MarketBeat
Is Sagimet Biosciences Inc. stock trending bullish2025 Volume Leaders & Free Safe Capital Growth Stock Tips - mfd.ru
Is Sagimet Biosciences Moving Closer to Market-Ready Treatments - Kalkine Media
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences - The Manila Times
Hear Sagimet Biosciences at Guggenheim and Oppenheimer investor events - Stock Titan
A Look At Sagimet Biosciences (SGMT) Valuation After Denifanstat’s Phase 3 Acne Trial Success - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: Thermo Fisher (TMO), Tenet Healthcare (THC) - The Globe and Mail
Sagimet Biosciences (NASDAQ:SGMT) Coverage Initiated by Analysts at Guggenheim - Defense World
After Clearing Up Acne, Sagimet Stock Rises - Barron's
Sagimet a new buy at Guggenheim on promise of MASH, acne asset - Seeking Alpha
Sagimet Biosciences (NASDAQ:SGMT) Earns Buy Rating from Analysts at Guggenheim - MarketBeat
Sagimet Biosciences' (SGMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
New acne mechanism shows 1-year durability in Phase III, says Sagimet - The Pharma Letter
Sagimet Therapeutics: Strengthened FASN-Inhibition Safety Profile and Advancing Phase 2 Programs Support Buy Rating - TipRanks
Sagimet stock rises after positive Phase 3 safety data for acne drug By Investing.com - Investing.com South Africa
Sagimet stock rises after positive Phase 3 safety data for acne drug - Investing.com Australia
Sagimet Biosciences announces license partner Ascletis issues results for ASC40 - TipRanks
Sagimet Biosciences Reports Positive Phase 3 Acne Data - TipRanks
Sagimet Biosciences Inc Announces Positive Phase 3 Acne Trial Results - TradingView
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne - The Manila Times
Sagimet’s Denifanstat: China Phase III Safety Data Isn’t A Negative Signal (NASDAQ:SGMT) - Seeking Alpha
Sagimet down as Chinese partner posts late-stage trial data for acne therapy - MSN
Sagimet Biosciences (NASDAQ:SGMT) Stock Rating Upgraded by Barclays - MarketBeat
Once-a-day acne pill shows 40-week safety in 240 Chinese patients - stocktitan.net
Barclays Initiates Coverage of Sagimet Biosciences (SGMT) with Equal-Weight Recommendation - Nasdaq
Barclays Initiates Coverage on Sagimet Biosciences With Equal Weight Rating, $8 Price Target - marketscreener.com
Is Sagimet Biosciences Inc stock influenced by commodity pricesWeekly Profit Analysis & Reliable Breakout Forecasts - baoquankhu1.vn
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Sagimet Biosciences enters global license agreement with TAPI - MSN
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) Shares Down 0.5%Here's Why - MarketBeat
Trend Review: Can Sagimet Biosciences Inc deliver alphaWeekly Market Outlook & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Will Sagimet Biosciences Inc stock keep outperforming rivalsJuly 2025 WrapUp & Fast Entry High Yield Tips - Bộ Nội Vụ
Death Cross: Can Sagimet Biosciences Inc stock reach 100 price targetPortfolio Risk Summary & High Return Trade Opportunity Guides - Bộ Nội Vụ
Sagimet Biosciences: Advancing FASN Inhibitor Pipeline and Multi-Indication Opportunities Support Buy Rating and $26 Target - TipRanks
Why Sagimet Biosciences Inc. stock remains on watchlistsJuly 2025 Recap & AI Powered Market Entry Strategies - Улправда
After-Hours Biotech Gainers: RVMD Soars On Merck Deal Talks Reports, SXTC, KALV, SGMT Rally - RTTNews
How Sagimet Biosciences Inc. stock performs in stagflationJuly 2025 Fed Impact & Verified Short-Term Plans - Улправда
Why retail investors favor Sagimet Biosciences Inc. stockQuarterly Investment Review & AI Based Buy and Sell Signals - Улправда
Why Sagimet Biosciences Inc. stock could be next big winnerRisk Management & Reliable Breakout Forecasts - Улправда
Can Sagimet Biosciences Inc. stock beat market expectations this quarterJuly 2025 PreEarnings & AI Driven Price Forecasts - Улправда
Published on: 2026-01-08 19:16:00 - Улправда
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference - The Manila Times
Falcon Technoprojects India Limited Chart Enters High Volatility ZoneTake Profit Strategies & Fast Growing Trading Ideas - earlytimes.in
Sagimet Biosciences Inc. (SGMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
We're Hopeful That Sagimet Biosciences (NASDAQ:SGMT) Will Use Its Cash Wisely - Yahoo Finance
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Disc Medicine (IRON) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $26 - 富途牛牛
Finanzdaten der Sagimet Biosciences Inc-Aktie (SGMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sagimet Biosciences Inc-Aktie (SGMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chauche Thierry | Chief Financial Officer |
Feb 10 '26 |
Sale |
5.36 |
1,312 |
7,033 |
15,688 |
| Martins Eduardo Bruno | Chief Medical Officer |
Feb 10 '26 |
Sale |
5.36 |
3,640 |
19,511 |
103,296 |
| Rozek Elizabeth | Chief Legal & Admin. Officer |
Feb 10 '26 |
Sale |
5.36 |
2,622 |
14,054 |
190,959 |
| Kemble George | Executive Chairman |
Nov 20 '25 |
Sale |
7.69 |
37,688 |
289,979 |
81,005 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):